• Crinetics highlighted long-term follow-up data at ENDO 2026 for once-daily oral PALSONIFY in adults with acromegaly.
• Extension studies showed durable disease control in patients switched from injectable standard care, with symptoms generally remaining steady over time.
• In previously uncontrolled patients, treatment improved biochemical control over extended follow-up, supporting use beyond initial trial periods.
• Tumor assessments were largely stable, with some patients showing reductions, reinforcing the product’s positioning as a long-term oral alternative.
• Safety remained broadly consistent with earlier experience, with no new signals reported across the pooled extension population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606141445OMX_____CNEWS_EN_GNW9746602_en) on June 14, 2026, and is solely responsible for the information contained therein.